[Attenuating effect of a new pharmacological agent (Dantrolene sodium) on spasticity].
D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D003620:Dantrolene / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy*; D010243:Paralysis / Q000188:drug therapy*
D006827:Hydantoins; D009125:Muscle Relaxants, Central; D003620:Dantrolene
L'effet atténuant d'un nouvel agent pharmacologique (Dantrolene sodium) sur la spasticité.